From the Journals

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

Share

  • 1

    Study conducted across eight cancer centers from 2012-

  • 2

    Higher risks of renal impairment, ototoxicity, and neuropathy in EPx4 versus BEPx

  • 3

    41% of patients displayed reduced eGFR below normal levels.

  • 4

    Correlations found between eGFR and future hypertension risk.

  • 5

    BEPx4 linked to increased odds of Raynaud phenomenon.

  • 6

    Physical activity noted as a protective factor for health outcomes.

  • 7

    Limitations in the study include lack of pretreatment creatinine data.

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • by Kerri Miller

  • February 25, 2026

  • 5 min

Related Content

Exercise Matters Following Cancer

Postdiagnosis physical activity was associated with lower cancer mortality across several cancer types.

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Why Scientists Are Revisiting a Polarizer

The nation’s top cancer institute takes a closer look at a disputed drug.